Voxelotor

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 212 publications

Rethinking Sickle Cell Disease as a Systemic Vasculopathy.

Rethinking Sickle Cell Disease as a Systemic Vasculopathy.

Journal: Cells

Published: January 02, 2026

Optimizing the right time to start sickle cell therapies.

Optimizing the right time to start sickle cell therapies.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.

Journal: Journal of comparative effectiveness research

Published: November 24, 2025

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease.

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries.

Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries.

Journal: Blood advances

Published: November 04, 2025

Low Use of FDA-Approved Medications for Sickle Cell Disease in Adults.

Low Use of FDA-Approved Medications for Sickle Cell Disease in Adults.

Journal: European journal of haematology

Published: October 23, 2025

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Journal: Molecular pharmaceutics

Published: September 07, 2025

Hemoglobin as a Molecular Glue: Toward Potent Inhibition of HbS Polymerization in Sickle Cell Disease.

Hemoglobin as a Molecular Glue: Toward Potent Inhibition of HbS Polymerization in Sickle Cell Disease.

Journal: Advanced healthcare materials

Published: September 03, 2025

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice.

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: August 15, 2025

Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective.

Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective.

Journal: Drug testing and analysis

Published: June 12, 2025

Voxelotor (Oxbryta) Binds Multiple Hemoglobin Sites and Influences Protein Structure.

Voxelotor (Oxbryta) Binds Multiple Hemoglobin Sites and Influences Protein Structure.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2025

Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies.

Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies.

Journal: American journal of hematology

Published: June 02, 2025

Showing 1-12 of 212

Last Updated: 04/28/2026